Welcome to our dedicated page for Clearmind Medici SEC filings (Ticker: CMND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clearmind Medicine Inc. (CMND) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Clearmind submits current reports on Form 6-K and annual reports on Form 20-F under the Securities Exchange Act of 1934, reflecting its status as a clinical-stage psychedelic pharmaceutical biotech company listed on Nasdaq and the Frankfurt Stock Exchange.
Through these filings, investors can review press releases that are formally incorporated by reference into Clearmind’s registration statements on Form F-3 and Form S-8. Recent Form 6-K reports have attached announcements about the FDA-approved Phase I/IIa clinical trial of CMND-100 for alcohol use disorder, including positive top-line results from the first cohort, Data and Safety Monitoring Board approval to continue the trial, and expansion of the multinational clinical-site network. Other 6-K filings describe capital-raising transactions such as registered direct offerings of common shares and pre-funded warrants, with stated uses of proceeds for operating expenses, research and development, clinical and pre-clinical testing, working capital, and general corporate purposes.
Clearmind’s filings also document corporate actions relevant to CMND stock, including a 1-for-40 reverse share split and Nasdaq notifications regarding minimum bid price and stockholders’ equity requirements. These documents outline how the company has addressed exchange listing criteria and how related matters are monitored by Nasdaq. In addition, the filings identify Clearmind’s principal executive offices in Vancouver, British Columbia, and provide details on its intellectual property-focused business model and clinical-stage status.
On Stock Titan, Clearmind’s SEC filings are updated as new documents are posted to EDGAR. AI-powered summaries help explain the context and key points of lengthy reports, making it easier to locate information on clinical trial disclosures, financing terms, and listing compliance without reading every page in detail. Users can also review historical filings to understand how Clearmind’s development programs, capital structure, and regulatory communications have evolved over time.
Clearmind Medicine Inc. reported progress in its ongoing FDA-approved Phase I/IIa clinical trial of CMND-100, a proprietary non-hallucinogenic MEAI-based oral drug candidate for Alcohol Use Disorder. The company has successfully completed treatment and follow-up for 18 participants, marking a key early-stage milestone in assessing safety, tolerability, pharmacokinetics, and preliminary efficacy.
Clearmind also completed treatment for four additional participants at its Tel Aviv clinical center, highlighting expanding enrollment and operational strength at its Israeli sites. The trial is being run at leading institutions including Yale University, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. Clearmind describes itself as a clinical-stage neuroplastogens pharmaceutical biotech with nineteen patent families and 31 granted patents focused on non-hallucinogenic, second-generation therapeutics for underserved conditions such as Alcohol Use Disorder.
Clearmind Medicine Inc., a clinical-stage biotech company focused on non-hallucinogenic, second-generation neuroplastogen-derived therapeutics, has filed a patent application in India for innovative psychedelic-based compounds aimed at treating mental health disorders and addiction. The application, submitted to the Indian Patent Office, extends the company’s global intellectual property portfolio and builds on its exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem.
The patent seeks to protect novel compounds designed to address limitations of classical psychedelics, with the goal of providing potentially safer, more effective and scalable treatments for underserved mental health and addictive conditions. Clearmind reports that its intellectual property portfolio currently includes nineteen patent families and 31 granted patents, and it plans to continue pursuing additional patents and related IP opportunities.
Clearmind Medicine Inc. files a post-effective amendment registering the resale of up to 331,949 common shares issuable upon exercise of January 2024 PIPE Warrants. The prospectus combines previously effective registration statements and covers shares issuable from time to time upon warrant exercise.
The selling shareholders will receive net proceeds from any resale; the company will not receive proceeds unless warrants are exercised for cash. The filing notes 2,394,806 common shares outstanding as of March 24, 2026 and states the registered shares equal approximately 15.89% of outstanding shares prior to the offering.
Clearmind Medicine Inc. files a post-effective amendment registering up to 331,949 common shares for resale by selling shareholders, representing shares issuable upon exercise of January 2024 PIPE Warrants, upon effectiveness.
The combined prospectus consolidates prior registrations and updates warrant adjustments following financings and a one-for-40 reverse split. The company will not receive proceeds from resales; however, it may receive proceeds if warrants are exercised for cash. The filing discloses 2,394,806 common shares outstanding as of March 24, 2026 and lists selling holders with per-holder maximums and 4.99%/9.99% beneficial ownership limits on warrant exercises.
Clearmind Medicine Inc. reported continued progress in the third cohort of its FDA-approved Phase I/IIa trial of CMND-100, a non-hallucinogenic MEAI-based oral drug candidate for treating Alcohol Use Disorder. Patients at Yale University and Johns Hopkins University are moving through treatment with no serious adverse events reported to date, supporting the drug’s early safety and tolerability profile.
The multinational, multicenter study is designed to assess safety, tolerability, pharmacokinetics, and preliminary efficacy in moderate to severe Alcohol Use Disorder. Clearmind describes itself as a clinical-stage neuroplastogens-focused biotech with an intellectual property portfolio of nineteen patent families, including 31 granted patents.
Clearmind Medicine Inc. reported that the Intellectual Property Department in Hong Kong has published six patents covering its next-generation psychedelic-based combination therapies. These patents center on formulations that pair Palmitoylethanolamide (PEA), supplied through its partnership with NeuroThera Labs, with several classic and innovative psychedelic compounds.
The combinations include PEA with MDMA, LSD, ketamine, ibogaine, psilocybin and DMT, aiming to enhance therapeutic potential and neuroplasticity while potentially improving safety and tolerability. Clearmind describes itself as a clinical-stage neuroplastogens biotech with an intellectual property portfolio of nineteen patent families, including 31 granted patents.
L.I.A. Pure Capital Ltd. filed an amendment to a Schedule 13G reporting beneficial ownership in Clearmind Medicine Inc. The filing states 108,720 Common Shares, representing 5.0% of the class based on 2,088,806 shares outstanding as of the reporting date. The position consists of 20,470 currently held Common Shares, 93,231 shares issuable upon conversion of a convertible promissory note at a $1.25 floor conversion price, and 229,000 shares exercisable under a pre-funded warrant; exercise/conversion are subject to a 4.99% beneficial ownership blocker. The amendment is signed by Kfir Silberman as CEO on 03/16/2026.
Clearmind Medicine Inc. schedule filing: Capitalink Ltd. reports beneficial ownership of 107,943 Common Shares, representing 5.0% based on 2,088,806 shares outstanding as stated in the filing.
The filing breaks the position into (i) 32,693 Common Shares held, (ii) 93,231 Common Shares issuable upon conversion of a convertible promissory note at a $1.25 conversion price, and (iii) 229,000 Common Shares that may be acquired upon exercise of a pre-funded warrant, each within 60 days. The note and warrant include a blocker provision limiting ownership to "more than 4.99%" when combined with affiliates.